Cargando…

Sodium-glucose co-transporter-2 inhibitor mediated cardio-protection: does increase of hematocrit finally matter? Sub-analysis of a prospective, observational study

Detalles Bibliográficos
Autores principales:	Patoulias, Dimitrios, Papadopoulos, Christodoulos, Karagiannis, Asterios, Doumas, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278171/ https://www.ncbi.nlm.nih.gov/pubmed/35846411 http://dx.doi.org/10.5114/amsad.2022.116665

Ejemplares similares

Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Colchicine for the prevention of COVID-19 “hard” outcomes: All that glitters is not gold
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Time to assess the effects of sodium–glucose co‐transporter‐2 inhibitors on the ‘forgotten' right ventricle?
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Sodium–Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?
por: Doumas, Michael, et al.
Publicado: (2020)

Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Meta-Analysis Addressing the Efficacy and Safety of Antiplatelet Agents in Patients With COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Sodium-glucose co-transporter-2 inhibitors in the intensive care unit setting: Do we really need sodium increase, especially in sepsis?
por: Patoulias, Dimitrios
Publicado: (2023)

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Increased Hematocrit During Sodium-Glucose Cotransporter-2 Inhibitor Therapy
por: Heyman, Samuel N., et al.
Publicado: (2017)

The Associations between Kidney Function and Sexual Dysfunction among Males and Females with Type 2 Diabetes Mellitus
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Sodium–glucose co-transporter 2 inhibitors for the treatment of cardio-renal syndrome
por: Cice, Gennaro, et al.
Publicado: (2022)

Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review
por: Papadopoulos, Christodoulos, et al.
Publicado: (2020)

Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action
por: Athyros, Vasilios Gabriel, et al.
Publicado: (2016)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?
por: Athyros, Vasilios G, et al.
Publicado: (2011)

Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

The Impact of Metabolic Syndrome Components on Erectile Function in Patients with Type 2 Diabetes
por: Katsimardou, Alexandra, et al.
Publicado: (2023)

Increased Hematocrit During Sodium-Glucose Cotransporter 2 Inhibitor Therapy Indicates Recovery of Tubulointerstitial Function in Diabetic Kidneys
por: Sano, Motoaki, et al.
Publicado: (2016)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Comparison of three-fold converted hematocrit and micro-hematocrit in pregnant women
por: Kiya, Girum Tesfaye, et al.
Publicado: (2019)

Metaanálisis para evaluar el riesgo de infecciones respiratorias y síndrome de distrés respiratorio del adulto con los agonistas del receptor del péptido similar al glucagón tipo 1 en los ensayos de seguridad cardiovascular: consecuencias útiles para la pandemia de COVID-19
por: Patoulias, D., et al.
Publicado: (2022)

Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic()
por: Patoulias, D., et al.
Publicado: (2022)

Automated blood glucose monitor is insensitive to hematocrit variation and common saccharide interferents
por: Hendee, S, et al.
Publicado: (2010)

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
por: Akiyama, Hiroki, et al.
Publicado: (2023)

Sodium, Glucose and Dysregulated Glucagon Secretion: The Potential of Sodium Glucose Transporters
por: Armour, Sarah L., et al.
Publicado: (2022)

COVID-19: The Waterloo of governments, healthcare systems, and large health organizations
por: Doumas, Michael, et al.
Publicado: (2020)

Hematocrit and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2020)

Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and non‐diabetic CKD
por: Loutradis, Charalampos, et al.
Publicado: (2020)

Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Role of Selective Sodium-Glucose Co-Transporter-2 Inhibitors in Managing Cardio-Renal Complications in Type 2 Diabetes Mellitus: Beyond Glycemic Control
por: Onyali, Chike B, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fv7gp5via2g8q2l60159lbkgfg